- The company has supported the launch of Sri Lanka’s first robotic cardiac surgery program at Kings Hospital Colombo using the SSi Mantra 3.0 surgical robotic system.
- The program began with a robotic-assisted LIMA takedown, performed by SS Innovations founder and Chairman Dr. Sudhir Srivastava alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva.
- Kings Hospital has completed more than 25 robotic procedures in three weeks, according to a recent company video describing the program’s early activity.
- SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter.
- The company’s second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company’s installed base.
- The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is helping write a new chapter in Sri Lanka’s cardiac-surgery sector with the launch of the country’s first robotic cardiac surgery program at Kings Hospital Colombo, using the SSi Mantra 3.0 surgical robotic system.
At a glance
- Company
- SS Innovations International
- Ticker
- NASDAQ: SSII
- Announcement
- Expansion
- Location
- Colombo, Sri Lanka
Key figures
- Robotic procedures completed at Kings Hospital in three weeks
- more than 25
- Cumulative SSi Mantra installations at the end of the second quarter
- 224
- Countries with reported installations
- 12
- Second-quarter revenue
- $13.9 million
- Year-over-year increase in robotic procedures
- 143%
- Second-quarter robotic procedures
- 2,528
People
- Dr. Sudhir SrivastavaFounder and Chairman of SS Innovations
- Dr. Rajitha DeSilvaKings Hospital cardiothoracic surgeon
Products and programs
The program began with a robotic-assisted left internal mammary artery (“LIMA”) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, together with Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. The development was highlighted in a recent video from SS Innovations, which described the introduction of…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Corporate Communications
IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]
Questions around this news
How did the robotic cardiac surgery program in Colombo begin?
The initiative opened at Kings Hospital Colombo with a robot-assisted procedure to prepare the left internal mammary artery, commonly called the LIMA. SS Innovations founder and chairman Dr. Sudhir Srivastava performed it with cardiothoracic surgeon Dr. Rajitha DeSilva of the hospital. The release identifies this operation as the program’s starting point.
What early activity has Kings Hospital reported for its robotic surgery program?
Kings Hospital had carried out over 25 robotic procedures during the program’s first three weeks, according to a company video mentioned in the release. That figure describes activity at the hospital, while the company’s reported installation total and procedure volume cover its broader operations.
What company-wide operating figures did SS Innovations report for the second quarter?
The release says second-quarter revenue was $13.9 million and robotic procedures rose 143% year over year, reaching 2,528. It also reports 224 cumulative installations across 12 countries at quarter-end. These are company-reported figures and are distinct from the activity described at Kings Hospital.
What regulatory approvals is SS Innovations pursuing for its surgical robotic system?
The company is seeking clearance from the U.S. Food and Drug Administration and CE marking in Europe for the SSi Mantra system, according to the release. These are separate regulatory processes for market access in their respective regions; the release does not state that either authorization has been granted.
SEC filings
Earlier from SS Innovations International
- SS Innovations International (NASDAQ: SSII) Reports 79% Growth in SSi Mantra Procedures, Expands Global Reach
- SS Innovations International (NASDAQ: SSII) Turning India’s Surgical Robotics Opportunity Into a Global Growth Story
- SS Innovations International (NASDAQ: SSII) Record Q2 Revenue Signals Continued Momentum for SSi Mantra Robotic Surgery Platform
- SS Innovations International (NASDAQ: SSII) Reports Record Q2 Revenue of $13.9M, Up 39.4%
- SS Innovations International (NASDAQ: SSII) Expands Global Footprint on Fast-Growing Robotic Surgery Market
